Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Trastuzumab (ausschließlich 600mg i.e.D.), ATC L01FD01 für die Zeit 01.06.2026 - 31.05.2028

Section 130a, paragraph 8 of the SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Trastuzumab (exclusively 600mg i.e.D.), ATC L01FD01, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the approval model for the aforementioned active substance will come into force for the first time on 01.06.2026 and will end on 31.05.2028. It will automatically end with the entry into force of the exclusive contract, regardless.